



**DexTech**  
Know-how in Translational Research

**Press release 2022-05-11**

DexTech Medical AB, 556664-6203

## **Report from the Extraordinary General Meeting**

Today, May 11, 2022, the Extra General Meeting of DexTech Medical AB was held. Below is a summary of the decisions made. All decisions were made by the required majority.

### **Determination of the number of board members and deputy board members**

The EGM resolved that the number of board members be increased by one member to a total of six members without deputies.

### **Determination of fees to the board**

The EGM resolved that fees shall be paid to the Chairman of the Board in the amount of SEK 200,000 calculated on a calendar year basis for the period until the next Annual General Meeting and that fees shall not be paid to other members.

### **Election of board**

The EGM decided to elect Andreas Segerros as a new ordinary board member and Svante Wadman, Per-Olov Asplund, Rolf Eriksson, Anders Holmberg and Sten Nilsson were re-elected. At the subsequent statutory board meeting, Andreas Segerros was elected new chairman of the board.

### **For further information**

Gösta Lundgren - CFO  
DexTech Medical AB  
Phone: +46 (0) 707104788  
Email: [gosta.lundgren@dextechmedical.com](mailto:gosta.lundgren@dextechmedical.com)

***DexTech Medical AB** is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to out-license the respective drug candidate no later than after completing the Phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.*